1992
DOI: 10.1007/bf01832357
|View full text |Cite
|
Sign up to set email alerts
|

Monitoring the chemosensitizing effects of toremifene with flow cytometry in estrogen receptor negative multidrug resistant human breast cancer cells

Abstract: The clinical study of compounds that modulate multidrug resistance in cancer cells has been hindered by both the toxicities of these agents and the inability to monitor their effectiveness at a cellular level. The non-steroidal triphenylethylene toremifene is well tolerated clinically and can sensitize multidrug resistant cells to the effects of doxorubicin in vitro. The chemosensitizing properties of toremifene in estrogen receptor negative, multidrug resistant MDA-A1 human breast cancer cells were studied us… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

1993
1993
2001
2001

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 15 publications
(1 citation statement)
references
References 8 publications
0
1
0
Order By: Relevance
“…Doxorubicin has been previously reported to block MDA-MB-231 cells in G 2 (22). To examine whether PA and doxorubicin affect cell cycle distribution, MDA-MB-231 cells were treated with PA (0-50 µM) and doxorubicin (0.05 µg/ml) for 48 hr, and the cell cycle distribution was determined.…”
Section: Effect Of Pa and Doxorubicin On Cell Cycle Phase Distributionmentioning
confidence: 99%
“…Doxorubicin has been previously reported to block MDA-MB-231 cells in G 2 (22). To examine whether PA and doxorubicin affect cell cycle distribution, MDA-MB-231 cells were treated with PA (0-50 µM) and doxorubicin (0.05 µg/ml) for 48 hr, and the cell cycle distribution was determined.…”
Section: Effect Of Pa and Doxorubicin On Cell Cycle Phase Distributionmentioning
confidence: 99%